HealthBeacon's ICMS: 19% More Patients on Therapy at Month 12​ Improvement

Primary Objective:​

To compare literature reported persistence rates to those of HealthBeacon patients, to demonstrate the impact of the ICMS on therapy continuation over a 12 month period.

Secondary Objective:

To determine the relationship between patient variables and persistence to therapy, i.e. therapeutic area, age and gender, to better understand the many factors influencing patient medication taking behaviours.

Results:

70.6% of HealthBeacon patients remained on treatment at Month 12, representing an 18.7% relative increase over previously reported persistence rates during the same time.​

Relative improvements were found across all therapeutic areas:​

• 12 Month HB Patient Persistence in Dermatology: 73.9% (+28% relative increase compared to the literature)​
• 12 Month HB Patient Persistence in Rheumatology: 67.4 % (+21.2% relative increase)​
• 12 Month HB Patient Persistence in Gastroenterology: 72.3% (+13.1% relative increase)

Conclusion:

The findings suggest that HealthBeacon’s ICMS provides a considerable improvement in persistence when compared to previous reports of patient persistence for those without a support platform. A relative 18.7% increase was found across all therapeutic areas.

Evaluation of the adoption of a connected device to monitor and improve patient’s adherence and persistence to therapy using real-world data

Primary Objective:

Evaluate the adoption of a connected device to monitor and improve patients adherence and persistence to therapy using real world data [1]​

Results:

77% of the patient population adopted the technology

The 23% of patients that did not adopt the technology cited the following reasons:

Conclusion:

With 77% of patients adopting the technology this study demonstrates that patient centred-design that deploys passive adherence monitoring can overcome barriers to adoption of technology.

The HealthBeacon Injection Care Management System (ICMS) shows Improved Adherence to Gastroenterological, Dermatological and Rheumatological Treatments​

Primary Objective:

To compare HealthBeacon’s adherence rates to those previously reported in the literature to demonstrate the benefits of HealthBeacon’s ICMS on medication adherence​.

Secondary Objective:​

To determine the relationship between patient variables and persistence to therapy, i.e. therapeutic area, age and gender, to better understand the many factors influencing patient medication taking behaviours

Results:

HealthBeacon’s adherence was strong overall with an MPR of 0.865 (SD=0.037).​

Age​

• Regression showed adherence increased significantly with age (F(4,22)=7.47, p<.001), with post-hoc testing showing adherence as significantly highest in the oldest age group (MPR=0.913, SD=0.054).​

Therapeutic Area​​

• For those on rheumatological treatments, the proportion of HealthBeacon patients with MPR ≥0.80 (66%) significantly exceeded the 95% confidence interval of reported studies (45-62%).
• HealthBeacon MPR was also high for gastroenterological (87.3%) and dermatological (86.5%) treatments, comparing favorably with previous reports in each (62% and 61%, respectively). Improvements of up to 26%, and an average 25% increase in MPR was seen.​

Gender​​

• Adherence differences in gender were not found in HealthBeacon’s data, which have been previously reported in gastroenterological and rheumatological treatments, respectively4,8. Adherence was extremely similar between males (86.80%, SD= 3.03%) and females (86.13%, SD= 4.44%)

Conclusion:

• Amongst HealthBeacon patients, adherence appears to increase significantly with age, mirroring age effects seen in the literature. ​
• Differences between gender were not identified and were potentially mitigated by the HealthBeacon ICMS.
• There were no significant differences found in adherence between therapeutic area